Abstract
In Canada, there are two separate review processes for the public reimbursement of drugs: one for cancer drugs (originally called the Joint Oncology Drug Review [JODR] and now called the pan-Canadian Oncology Drug Review [pCODR]) and one for drugs in all other disease areas (called the Common Drug Review). We explore whether a justification that is derived from an economic perspective has been provided, in Canada or elsewhere, for cancer drugs to have a separate reimbursement review process (i.e. to be ‘treated separately’) relative to drugs in all other disease areas. Literature reviews and internet searches were undertaken to identify, collect and analyze relevant documents that would provide information regarding whether an economic rationale has been provided for cancer drugs to be treated separately for resource allocation purposes. Although a number of reasons for cancer drugs to be treated separately were cited both by the JODR and pCODR and in the peer-reviewed literature, a rationale derived from an economic perspective did not appear to be documented. From an economic perspective, separating cancer drugs for resource allocation purposes is likely to impede drug plan decision makers’ ability to allocate resources in a manner that maximizes the total aggregate health benefit for the population from available resources. While we acknowledge the challenges that cancer drugs pose to drug reimbursement decision makers, we suggest that separating the reimbursement review of cancer drugs requires further scrutiny.
Similar content being viewed by others
Notes
In this paper we included all rationales given for cancer drugs to be treated separately from drugs in other disease areas for resource allocation purposes and then appraised whether any of these rationales were derived from an economic perspective.
References
Gafni A, Birch S. Incremental cost-effectiveness ratios (ICER): the silence of the lambda. Soc Sci Med. 2006;62:2091–100.
Gold MR, Siegel JE, Russel LB, Weinstein MC (eds) Cost-effectiveness in health and medicine. 1996. New York: Oxford University Press.
National Institute for Clinical Excellence. Guide to the methods of technology appraisal. http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed 19 Aug 2013.
Weinstein MC, Stason WB. Foundations of cost effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–21.
Pan-Canadian Oncology Drug Review. Frequently Asked Questions about the pCODR. n.d. http://www.pcodr.ca/wcpc/portal/Home/General_PC/FAQs?_afrLoop=25145554173000&_afrWindowMode=0&_adf.ctrl-state=181u3zxy2t_477. Accessed 14 Aug 2013.
Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ. 2002;11:185–91.
Gafni A, Birch S. Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ. 1991;10:329–42.
Mooney G. Economics, Medicine and Health Care. Brighton: Wheatsheaf Books; 1986.
Le Grand J. Equity and choice: an essay in economics and applied philosophy. London: Harper Collins; 1991.
Joint Oncology Drug Review. April 2008 JODR Newsletter. 2008. http://www.myelomacanada.ca/docs/jodr%20newsletter%20april%202008.pdf?LanguageID=EN-US. Accessed 21 Aug 2013.
Joint Oncology Drug Review. July 2008 JODR Newsletter. 2008. http://www.myelomacanada.ca/docs/jodr%20newsletter%20july%202008.pdf?LanguageID=EN-US. Accessed 21 Aug 2013.
Joint Oncology Drug Review. Fall 2008 JODR Newsletter. 2008. Private Communication from the Industry Oncology Working Group.
Koester O. P/T Oncology Collaborative Initiative (Joint Oncology Drug Review), Canadian Association for Healthcare Reimbursement Meeting. 2008. http://www.cahrp.ca/resources/WRM-OlafKoester.pdf. Accessed 21 June 2010.
Wilson K, Koester O. Pan-Canadian Oncology Drug Review. Presentation given at pCDOR Stakeholder Sessions meeting on January 21, 2010. 2010. Private communication from Heather McDonald, obtained via attendance at Stakeholder Session meeting.
Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S. Evidence and values: requirements for public reimbursement of drugs for rare diseases: a case study in oncology. Can J Clin Pharmacol. 2009;16(2):e273–81.
Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Addendum to CADTH’s Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. 2009. http://www.cadth.ca/media/pdf/H0405_Guidance_for_Oncology_Prodcuts_gr_e.pdf. Accessed 5 June 2013.
Drummond M, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
Mason A, Drummond MF. Public funding of cancer drugs: is NICE getting nastier? Eur J Cancer. 2009;45:1188–92.
National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatment. July 2009. http://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2. Accessed 1 Oct 2014.
Martikainen J, Rajaniemi S. Drug reimbursement systems in EU Member States, Iceland and Norway. 2002. http://helda.helsinki.fi/bitstream/handle/10138/13932/Drug_reimbursement.pdf?sequence=1. Accessed 7 Feb 2011.
Pan-Canadian Oncology Drug Review. Frequently asked questions about the pCODR. n.d. http://www.pcodr.ca/wcpc/portal/Home/General_PC/FAQs?_afrLoop=2334522631803000&_afrWindowMode=0&_adf.ctrl-state=yuukazrq2_4#q4. Accessed 3 Aug 2013.
Acknowledgements
Dr. Heather McDonald was responsible for conception and planning of the work that led to this paper and for preparing the draft and final submitted version of this paper. Drs. Charles, Elit and Gafni were responsible for conception and planning of the work that led to this paper and for critical revision of the manuscript for important intellectual content. No funding was received by any of the authors for the preparation of this paper. Heather McDonald is employed by Bayer Inc., but the work on this paper was part of a PhD dissertation. This paper was not seen by Bayer Inc. personnel, and Bayer Inc. did not have input on the content of this paper.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material [ESM].
Rights and permissions
About this article
Cite this article
McDonald, H., Charles, C., Elit, L. et al. Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?. PharmacoEconomics 33, 235–241 (2015). https://doi.org/10.1007/s40273-014-0238-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-014-0238-7